Zydus Lifesciences Ltd.
BSE: 532321 | NSE: ZYDUSLIFE
Mid Cap | Pharmaceuticals & Drugs
942.55
3.35 (0.36%) Zydus Lifesciences informs about press release
Date: 27-11-2025Zydus Lifesciences has informed that it enclosed press release titled ‘Zydus receives tentative approval from USFDA for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg.’.
The above information is a part of company’s filings submitted to BSE.